Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema
Aim: This study aimed to estimate the relative efficacy between garadacimab 200 mg once monthly (200 QM) and two dosing regimens of lanadelumab (300 mg once every 2 weeks [300 Q2W] and 300 mg once every 4 weeks [300 Q4W]) in adolescent/adult patients with hereditary angioedema (HAE) using matchin...
Saved in:
| Main Authors: | Sarah Walsh, Anja Haltner, Meaghan Bartlett, John Sears, Yinglei Li, Maebh Kelly, Simona Gavata-Steiger, Chiara Nenci, Iris Jacobs, Ingo Pragst, Neelanjana Ray, Imtiaz A Samjoo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2025-07-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Population Pharmacokinetic/Pharmacodynamic and Exposure–Response Modeling of Garadacimab in Healthy Volunteers and Patients With Hereditary Angioedema
by: Ramon Garcia, et al.
Published: (2025-05-01) -
Network Meta-Analysis of Pharmacological Therapies for Long-Term Prophylactic Treatment of Patients with Hereditary Angioedema
by: Sarah Walsh, et al.
Published: (2025-05-01) -
Evolution of Treatments for Hereditary Angioedema in Italy: Use of Lanadelumab in Clinical Practice
by: Marta Nugnes, et al.
Published: (2025-06-01) -
Hereditary angioedema plasma proteomics following specific plasma kallikrein inhibition with lanadelumab
by: Dan Sexton, et al.
Published: (2025-05-01) -
Prediction of hereditary angioedema during attacks in patients with recurrent angioedema: Awareness at a glance with the hereditary angioedema prediction score
by: Semra Demir, et al.
Published: (2025-04-01)